StonvexLoading…
StonvexStonvexStonvexCore line items from LIVN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $362.26M | $1.39B | $1.03B | $669.38M |
Operating Income | $41.47M | $199.39M | $156.81M | $102.80M |
Net Income | $22.29M | $-242.47M | $-273.38M | $-300.16M |
EPS (Diluted) | $0.40 | $-4.45 | $-5.01 | $-5.51 |
Total Assets | $2.52B | $2.61B | $2.56B | $2.51B |
Total Liabilities | $1.31B | $1.41B | $1.40B | $1.38B |
Cash & Equivalents | $539.71M | $635.55M | $646.08M | $593.64M |
Free Cash Flow OCF − CapEx | $926.00K | $173.29M | $123.13M | $60.95M |
Shares Outstanding | 54.90M | 54.65M | 54.61M | 54.59M |